REGULATION OF SGLT-2 BY THE SYMPATHETIC NERVOUS SYSTEM

被引:0
|
作者
Schlaich, Markus [1 ]
Elliott, Rosemary [1 ]
Rudnicka, Caroline [1 ]
Matthews, Vance [1 ]
机构
[1] Univ Western Australia, Dobney Hypertens Ctr, Nedlands, WA, Australia
关键词
D O I
10.1097/01.hjh.0000501008.46096.cd
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
OS 33-04
引用
收藏
页码:E394 / E394
页数:1
相关论文
共 50 条
  • [41] SGLT-2 inhibitors and their potential in the treatment of diabetes
    Rosenwasser, Rebecca F.
    Sultan, Senan
    Sutton, David
    Choksi, Rushab
    Epstein, Benjamin J.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2013, 6 : 453 - 467
  • [43] SGLT-2 inhibitors for the prevention of recurrent nephrolithiasis
    Sakhaee, Khashayar
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 387
  • [45] Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
    Grempler, R.
    Thomas, L.
    Eckhardt, M.
    Himmelsbach, F.
    Sauer, A.
    Sharp, D. E.
    Bakker, R. A.
    Mark, M.
    Klein, T.
    Eickelmann, P.
    DIABETES OBESITY & METABOLISM, 2012, 14 (01): : 83 - 90
  • [46] A study on the pharmacovigilance of various SGLT-2 inhibitors
    Dong, Yanwen
    Wang, Yangyang
    Lan, Xiaomei
    Zeng, Huiyan
    FRONTIERS IN MEDICINE, 2025, 11
  • [47] TREATMENT OF OBESITY WITH SGLT-2: OUR RESULTS
    Fazio, G.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2024, 26
  • [48] HFpEF: SGLT-2 even without Diabetes
    Franke, Katharina
    AKTUELLE KARDIOLOGIE, 2022, 11 (01) : 10 - 10
  • [49] SGLT-2 inhibition and glucagon: Cause for alarm?
    Kibbey, Richard G.
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2015, 26 (07): : 337 - 338
  • [50] SGLT-2 inhibitors in diabetes: a focus on renoprotection
    Gonzalez, Diego Ennes
    Foresto, Renato Demarchi
    Ribeiro, Artur Beltrame
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2020, 66 : S17 - S24